Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
Fiche publication
Date publication
janvier 2016
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr RIOS Maria
Tous les auteurs :
Patrikidou A, Domont J, Chabaud S, Ray-Coquard I, Coindre JM, Bui-Nguyen B, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Pérol D, Emile JF, Blay JY, Le Cesne A,
Lien Pubmed
Résumé
The added value of tumoural genomic profiles to conventional clinico-biological factors to predict progression-free survival (PFS) and overall survival (OS) was prospectively investigated in patients with advanced gastrointestinal stromal tumours (GIST) treated in the BFR14 study.
Mots clés
Antineoplastic Agents, administration & dosage, Biomarkers, Tumor, genetics, DNA Mutational Analysis, Disease-Free Survival, Exons, Female, France, Gastrointestinal Neoplasms, drug therapy, Gastrointestinal Stromal Tumors, drug therapy, Humans, Imatinib Mesylate, administration & dosage, Kaplan-Meier Estimate, Male, Mutation, Predictive Value of Tests, Proportional Hazards Models, Protein Kinase Inhibitors, administration & dosage, Proto-Oncogene Proteins c-kit, genetics, Risk Factors, Time Factors, Treatment Outcome
Référence
Eur. J. Cancer. 2016 Jan;52:173-80